NR1I2 and breast carcinoma: On the other hand, it was demonstrated that IS is able to inhibit breast cancer cells both in vitro and in vivo through the binding with AhR and pregnane X receptor (PXR), while the enhanced expression of IS-producing enzymes is a favorable survival marker of breast cancer patients [57].